Tissium raises €30M in equity funding, €30M in debt
A French startup which uses a novel technology to reconstruct damaged tissue and restore it to its natural state has raised €30m in equity funding and taken out up to €30m in debt financing, it said t... The funds will be used to roll out its tech in the US. Medtech Tissium raises €30M in equity funding, €30M in debt The funds will be used to roll out its tech in the US.
Key Takeaways
- John Reynolds 3 hours ago Share Share Send email Copy link A French startup which uses a novel technology to reconstruct damaged tissue and restore it to its natural state has raised €30m in equity funding and taken out up to €30m in debt financing, it said today.
Tissium has developed materials called "biomorphic programmable polymers" that act as an adhesive, which bind nerves together inside tissue, circumventing the need for invasive stitches.
- Tissium's technology is used to repair heart defects, hernias, and damaged nerves.
Two of its products- one for nerve repair, one for hernia treatment- have received approval by the US Food and Drug Administration (FDA).
- Existing investors include Mérieux Développement and Cathay.
- The funding will be used to finance the rolling out of its tech in the US, and fund clinical trials as it looks to expand the tech to other areas of healthcare.
Christophe Bancel, CEO and co-founder, Tissium, said: "We are now executing on our transition into a commercial-stage MedTech company while continuing to advance a differentiated pipeline built on the same underlying biomorphic polymer platform.
- What would you like us to deliver to you?
The funds will be used to roll out its tech in the US. Medtech Tissium raises €30M in equity funding, €30M in debt The funds will be used to roll out its tech in the US. John Reynolds 3 hours ago Share Share Send email Copy link A French startup which uses a novel technology to reconstruct damaged tissue and restore it to its natural state has raised €30m in equity funding and taken out up to €30m in debt financing, it said today.
Tissium has developed materials called "biomorphic programmable polymers" that act as an adhesive, which bind nerves together inside tissue, circumventing the need for invasive stitches. Its goal is to reduce trauma to the surrounding tissue and improve recovery rates in patients. Tissium's technology is used to repair heart defects, hernias, and damaged nerves.
Two of its products- one for nerve repair, one for hernia treatment- have received approval by the US Food and Drug Administration (FDA). Tissium said the €30m equity Series D-2 investment round was led by an undisclosed new US -based family-owned institutional investor. The round has also been supported by new family offices, high net worth individuals and existing investors, it said.
For more details please read the original article at Tech.eu.
Continue Learning
Comments
Sign in to join the conversation